Navigation Links
MAQUET Cardiovascular Receives FDA Clearance for MEGA(TM), the World's First 8Fr. 50cc Intra-Aortic Balloon Catheter
Date:9/23/2009

FAIRFIELD, N.J., Sept. 22 /PRNewswire/ -- MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, announced today at the Transcatheter Cardiovascular Therapeutics (TCT) convention in San Francisco, Calif., that the U.S. Food and Drug Administration has cleared the company's MEGA(TM) 8Fr. 50cc intra-aortic balloon (IAB) catheter. As the world's first 50cc IAB with a true 8Fr. shaft, the MEGA has a smaller insertion point than traditional 50cc IABs and offers additional blood volume displacement for intra-aortic balloon counterpulsation. MEGA, compared to 40cc IABs, delivers 25 percent more blood volume displacement and provides improved unloading and augmentation.* The MEGA will be available for distribution in September 2009.

MEGA balloon's impact in patient care was recently noted in the clinical setting. "I recently admitted a critically ill, approximately 400-pound patient and inserted the MEGA 50cc balloon," stated George W. Christy, M.D., FACC, Interventional Cardiologist with Advocate Christ Medical Center's Transplant and Assist Device team in Oak Lawn, Ill. "The increased augmentation we observed from MEGA allowed us to stabilize the patient." Dr. Christy believes that "the MEGA gave us the needed window of time to consider further alternatives to manage this patient."

"The MEGA truly demonstrates MAQUET's firm commitment to improving patient outcomes," says Christian Keller, President of MAQUET Cardiovascular. "For some time now, physicians have been seeking increased hemodynamic support with IAB therapy. The MEGA 8Fr. 50cc meets this need while providing a smaller shaft size, setting a new standard in IAB technology."

MAQUET Cardiovascular recently acquired Datascope, a distinguished provider of gold-standard IABs and cardiac assist products. By uniting forces, MAQUET is even better positioned to advance patient care technology through innovations like the MEGA.

Since the MEGA has no step down between the catheter shaft and the balloon material, it may be inserted sheathless or through an 8 Fr. sheath. Because of its unique design, it can benefit patients presently using both 50cc and 40cc IABs. Additional benefits include a unique Durathane blow-molded balloon membrane, a full-length polyimide lumen with no gas lumen insert, and numerous safety features, such as a T-handle protector to keep the membrane tightly wrapped prior to use.

"We've designed the MEGA to provide outstanding performance for a wider range of patients while reducing the risk for vascular complications," added Keller. "At the same time, we've made it very easy to use for physicians, and we're confident that they'll find it to be a true advance in IAB therapy."

Intra-aortic balloon counterpulsation is an adjunctive therapy that is often used in patients with left ventricular failure and other cardiac conditions. When the IAB inserted into the patient's aorta counterpulsates with the heart, it augments coronary blood flow to increase myocardial oxygen supply and decrease myocardial oxygen demand.

"Since the MEGA is indicated for patients 5'4" and taller, I would generally use it as my standard balloon moving forward," said Dr. Christy. "It's straightforward, easy to insert, and compatible with all the standard consoles."

For more information about the MEGA, please visit www.datascope.com

INFORMATION ABOUT THE MAQUET GROUP

The MAQUET Group is the global market leader for Medical Systems, focusing on the Operating Room (OR) and Intensive Care Unit (ICU). The integrated products of MAQUET are specially designed to deliver optimal clinical treatment and therapy concepts within acute care hospitals. MAQUET provides innovative medical solutions from three Divisions:

  • Cardiovascular with products for cardiac assist (intra-aortic balloon counterpulsation therapy), coronary artery bypass surgery, heart valve repair, aneurysm and vascular repair, peripheral interventions and extracorporeal circulation.
  • Critical Care for intensive care ventilators and anesthesia machines
  • Surgical Workplaces for OR tables, lights and ceiling service units, prefabricated OR and ICU suites as well as telemedicine for the OR integration.

MAQUET is a subsidiary of the publicly-listed Swedish group of companies GETINGE AB, a company with over $2.8 billion in revenues (2008 fiscal year) and 12,800 employees worldwide. In 2008 MAQUET itself generated pro-forma revenues (including the acquisition of Datascope Corp.) of over $1.4 billion. The company now has 5,000 employees in 34 international sales and service organizations, as well as a network of more than 200 sales representatives.

www.maquet.com

www.getinge.com

MAQUET - The Gold Standard.

* In vitro data


'/>"/>
SOURCE MAQUET Cardiovascular
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MAQUET Cardiovascular Awarded New Contract by Novation
2. MAQUET opens North Americas first VARIOP prefabricated operating suite system
3. MAQUET Opens North Americas First VARIOP Prefabricated Operating Suite System, Allowing Space Reconfiguration in Hours, Less Disruption Than Traditional Construction
4. Terumo Corporation Announces Settlement of all Patent Litigation with Maquet Cardiovascular
5. R&J Public Relations Selected to Promote MAQUET Inc.s VARIOP Operating Room Suite in North America
6. MAQUET Cardiovascular Responds to Terumo Complaint About VASOVIEW Endoscopic Vessel Harvesting Systems
7. Cardica, Intuitive Surgical, MAQUET Cardiovascular and Transonic to Host Innovations in Revascularization Symposium
8. MAQUET Cardiovascular Launches HEARTSTRING III Proximal Seal System for Coronary Artery Bypass Graft Surgery
9. MAQUET Cardiovascular Announces Patent Infringement Complaints Against Terumo
10. ARJO / Getinge / Maquet Announces New West Coast Showroom Opening
11. Cardiogenesis Announces Successful Symposium at the Transcatheter Cardiovascular Therapeutics (TCT) Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... St. Petersburg, FL (PRWEB) , ... February 06, 2016 , ... ... AsSeenOnTV.pro are pleased to announce the launch of a new DRTV campaign with Belly ... rug. If having tried everything from sprays to puppy pads and find nothing works, ...
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the ... a variety of colors, assortments and packaging. This staple for Valentine’s Day is a ... location. , For Valentine’s Day, not only are long-stem roses available, but also ...
(Date:2/5/2016)... ... 05, 2016 , ... Successful recruitment and retention efforts, new ... initiatives have all marked the last 12 months at Roswell Park Cancer Institute ... nation’s oldest cancer center, Candace S. Johnson, PhD, outlined the many accomplishments of ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... announce the addition of micro-needling services in their Napa Valley office. The technique ... of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are part of only ...
(Date:2/5/2016)... Toronto, Ontario (PRWEB) , ... February 05, 2016 , ... ... the Scarborough General Hospital Burn Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned ... the Scarborough Hospital. He successfully completed his first three-year term as chief and began ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... 2016  Aralez Pharmaceuticals Inc. ("Aralez") today announced the ... Tribute Pharmaceuticals Canada Inc. ("Tribute") following approval of the ... The combined company will operate under Aralez Pharmaceuticals Inc. ... Canada , Ireland ... Under the terms of the Agreement and Plan of ...
(Date:2/5/2016)... , Feb. 5, 2016  Venice,s newest laser ... the first of its kind in the area ... through advanced laser treatment. The physician-owned and operated ... Suncoast by storm with its revitalizing skin ... advanced multi-wavelength Astanza Trinity technology. http://photos.prnewswire.com/prnh/20160204/329957 ...
(Date:2/5/2016)... , Feb. 5, 2016  Zimmer Biomet Holdings, Inc. ... the previously announced underwritten secondary offering of 11,027,558 shares ... consisting of affiliates of Blackstone and Goldman Sachs.  The ... initial price of $96.45 per share. The selling stockholders ...  Neither Zimmer Biomet nor any of its directors, officers ...
Breaking Medicine Technology: